» Articles » PMID: 36595377

Posttransplantation Cyclophosphamide Expands Functional Myeloid-derived Suppressor Cells and Indirectly Influences Tregs

Abstract

Posttransplantation cyclophosphamide (PTCy), given on days +3 and +4, reduces graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but its immunologic underpinnings are not fully understood. In a T-cell-replete, major histocompatibility complex-haploidentical murine HCT model (B6C3F1→B6D2F1), we previously showed that PTCy rapidly induces suppressive mechanisms sufficient to prevent GVHD induction by non-PTCy-exposed donor splenocytes infused on day +5. Here, in PTCy-treated mice, we found that depleting Foxp3+ regulatory T cells (Tregs) in the initial graft but not the day +5 splenocytes did not worsen GVHD, yet depleting Tregs in both cellular compartments led to fatal GVHD induced by the day +5 splenocytes. Hence, Tregs were necessary to control GVHD induced by new donor cells, but PTCy's impact on Tregs appeared to be indirect. Therefore, we hypothesized that myeloid-derived suppressor cells (MDSCs) play a complementary role. Functionally suppressive granulocytic and monocytic MDSCs were increased in percentages in PTCy-treated mice, and MDSC percentages were increased after administering PTCy to patients undergoing HLA-haploidentical HCT. PTCy increased colony-stimulating factors critical for MDSC development and rapidly promoted the generation of MDSCs from bone marrow precursors. MDSC reduction via anti-Gr1 treatment in murine HCT did not worsen histopathologic GVHD but resulted in decreased Tregs and inferior survival. The clinical implications of these findings, including the potential impact of expanded MDSCs after PTCy on engraftment and cytokine release syndrome, remain to be elucidated. Moreover, the indirect effect that PTCy has on Tregs, which in turn play a necessary role in GVHD prevention by initially transplanted or subsequently infused T cells, requires further investigation.

Citing Articles

Galectin-1 is associated with hematopoietic cell engraftment in murine MHC-mismatched allotransplantation.

Shaikh A, Gangaplara A, Kone A, Almengo K, Kabore M, Ali M Front Immunol. 2024; 15:1411392.

PMID: 39351218 PMC: 11439684. DOI: 10.3389/fimmu.2024.1411392.


Age and dose dependent changes to the bone and bone marrow microenvironment after cytotoxic conditioning with busulfan.

Abbasizadeh N, Burns C, Verrinder R, Ghazali F, Seyedhassantehrani N, Spencer J Front Cell Dev Biol. 2024; 12:1441381.

PMID: 39139448 PMC: 11319712. DOI: 10.3389/fcell.2024.1441381.


Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients.

Shanmugasundaram K, Napier S, Dimitrova D, Stokes A, Wilder J, Chai A Bone Marrow Transplant. 2024; 59(11):1513-1524.

PMID: 39134710 PMC: 11530367. DOI: 10.1038/s41409-024-02312-4.


Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome.

Choi E, Han J, Park H, Park H, Choi Y, Lee J Bone Marrow Transplant. 2024; 59(9):1329-1331.

PMID: 38977776 DOI: 10.1038/s41409-024-02364-6.


Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors.

Herr M, Balderman S, Wallace P, Zhang Y, Tario Jr J, Buxbaum N Transplant Cell Ther. 2024; 30(8):808.e1-808.e13.

PMID: 38801976 PMC: 11296899. DOI: 10.1016/j.jtct.2024.05.018.


References
1.
Yin J, Li L, Wang C, Zhang Y . Increased Galectin-9 expression, a prognostic biomarker of aGVHD, regulates the immune response through the Galectin-9 induced MDSC pathway after allogeneic hematopoietic stem cell transplantation. Int Immunopharmacol. 2020; 88:106929. DOI: 10.1016/j.intimp.2020.106929. View

2.
Millrud C, Bergenfelz C, Leandersson K . On the origin of myeloid-derived suppressor cells. Oncotarget. 2016; 8(2):3649-3665. PMC: 5356220. DOI: 10.18632/oncotarget.12278. View

3.
Demosthenous C, Sakellari I, Douka V, Papayanni P, Anagnostopoulos A, Gavriilaki E . The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD). J Clin Med. 2021; 10(10). PMC: 8150814. DOI: 10.3390/jcm10102050. View

4.
Kanakry C, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B . Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013; 5(211):211ra157. PMC: 4155575. DOI: 10.1126/scitranslmed.3006960. View

5.
Bhat D, Olkhanud P, Gangaplara A, Seifuddin F, Pirooznia M, Biancotto A . Early Myeloid Derived Suppressor Cells (eMDSCs) Are Associated With High Donor Myeloid Chimerism Following Haploidentical HSCT for Sickle Cell Disease. Front Immunol. 2021; 12:757279. PMC: 8669726. DOI: 10.3389/fimmu.2021.757279. View